Molecular and clinical features of KATP -channel neonatal diabetes mellitus in Japan

Pediatr Diabetes. 2017 Nov;18(7):532-539. doi: 10.1111/pedi.12447. Epub 2016 Sep 29.

Abstract

Background: There are few reports pertaining to Asian patients with neonatal diabetes mellitus (NDM) caused by activating mutations in the ATP-sensitive potassium channel genes (KATP-NDM).

Objectives: To elucidate the characteristics of Japanese patients with KATP-NDM.

Methods: By the amplification and direct sequencing of all exons and exon-intron boundaries of the KCNJ11 and ABCC8 genes, 25 patients with KATP-NDM were identified from a total of 70 patients with NDM. Clinical data were collected from the medical charts.

Results: Sixteen patients had mutations in KCNJ11 and nine in ABCC8. Eight novel mutations were identified; two in KCNJ11 (V64M, R201G) and six in ABCC8 (R216C, G832C, F1176L, A1263V, I196N, T229N). Interestingly, V64M caused DEND (developmental delay, epilepsy, neonatal diabetes) syndrome in our patient, while mutation of the same residue (V64G) had been reported to cause congenital hyperinsulinism. Mutations in ABCC8 were associated with TNDM (4/9) or isolated PNDM (5/9), whereas those in KCNJ11 were associated with more severe phenotypes, including DEND (3/16), iDEND (intermediate DEND, 4/16), or isolated PNDM (6/16). Switching from insulin to glibenclamide monotherapy was successful in 87.5% of the patients. Neurological improvement was observed in two patients, one with DEND (T293N) and one with iDEND (R50P) syndrome. Three others with iDEND mutations (R201C, G53D, and V59M) remained neurologically normal at 5, 1, and 4 years of age, respectively, with early introduction of sulfonylurea.

Conclusion: Overall, clinical presentation of KATP-NDM in Japanese patients was similar to those of other populations. Early introduction of sulfonylurea appeared beneficial in ameliorating neurological symptoms.

Keywords: KATP -channel; Japanese; neonatal diabetes; sulfonylurea.

MeSH terms

  • Amino Acid Substitution
  • Congenital Hyperinsulinism / blood
  • Congenital Hyperinsulinism / drug therapy
  • Congenital Hyperinsulinism / genetics
  • Congenital Hyperinsulinism / physiopathology
  • DNA Mutational Analysis
  • Diabetes Mellitus / blood
  • Diabetes Mellitus / drug therapy
  • Diabetes Mellitus / genetics*
  • Diabetes Mellitus / physiopathology
  • Drug Monitoring
  • Drug Resistance
  • Epilepsy / blood
  • Epilepsy / drug therapy
  • Epilepsy / genetics
  • Epilepsy / physiopathology
  • Female
  • Genetic Association Studies
  • Genetic Predisposition to Disease*
  • Glyburide / therapeutic use
  • Humans
  • Hyperglycemia / prevention & control
  • Hypoglycemia / prevention & control
  • Hypoglycemic Agents / therapeutic use
  • Infant
  • Infant, Newborn, Diseases / blood
  • Infant, Newborn, Diseases / drug therapy
  • Infant, Newborn, Diseases / genetics
  • Infant, Newborn, Diseases / physiopathology
  • Insulin / therapeutic use
  • Japan
  • Male
  • Mutation*
  • Potassium Channels, Inwardly Rectifying / chemistry
  • Potassium Channels, Inwardly Rectifying / genetics*
  • Psychomotor Disorders / blood
  • Psychomotor Disorders / drug therapy
  • Psychomotor Disorders / genetics
  • Psychomotor Disorders / physiopathology
  • Severity of Illness Index
  • Sulfonylurea Receptors / chemistry
  • Sulfonylurea Receptors / genetics*

Substances

  • ABCC8 protein, human
  • Hypoglycemic Agents
  • Insulin
  • Kir6.2 channel
  • Potassium Channels, Inwardly Rectifying
  • Sulfonylurea Receptors
  • Glyburide

Supplementary concepts

  • Developmental Delay, Epilepsy, and Neonatal Diabetes
  • Diabetes Mellitus, Permanent Neonatal